

# TABLE OF CONTENTS

INTRODUCTION

LIST OF ABBREVIATIONS

GLOSSARY

LIST OF ATTACHMENTS

Page

<b>I</b>	<b>GA</b>	<b>100</b>	<b>GENERAL ADMINISTRATION</b>
		<b>101</b>	<b>Sponsor Responsibility and Delegation of Responsibility</b>
		A	Fulfilling Regulatory Obligations
		B	Delegation of Responsibility
		C	Transfer of Responsibility to Contractors
		<b>102</b>	<b>Document Development and Change Control</b>
		A	Document Initiation and Approval Procedures
		B	Document Change Procedures
		C	Document Implementation
		<b>103</b>	<b>Sponsor Research Team Training</b>
		A	Training Plan
		B	Documentation of Training
		<b>104</b>	<b>Conflict of Interest Disclosure Requirements</b>
		A	Financial Disclosure for Sponsors and Investigators
		B	FDA Reporting Requirements
		<b>105</b>	<b>Vendor Selection and Agreements</b>
		A	Institutional Vendor Requirements
		B	Regulatory Aspects
		C	Vendor Audits
<b>II</b>	<b>RA</b>	<b>200</b>	<b>REGULATORY AFFAIRS</b>
		<b>201</b>	<b>FDA Contacts and Meetings</b>
		A	Oral and Written Correspondence with FDA
		B	Meetings with FDA
		<b>202</b>	<b>FDA Submissions</b>
		A	IND Development and Submission
		B	IND Amendments
		<b>203</b>	<b>FDA Reporting Requirements</b>
		A	Preparation of Reports
		B	Study Reporting
		<b>204</b>	<b>Gene Transfer Research</b>
		A	NIH RAC Submission and Study Initiation
		B	Reporting Requirements
<b>III</b>	<b>PD</b>	<b>300</b>	<b>CLINICAL PROTOCOL DEVELOPMENT</b>
		<b>301</b>	<b>Clinical Protocol Development</b>
		A	Writing the Clinical Protocol
		B	Protocol Review and Approval
		C	Protocol Amendments
		D	Case Report Forms
		<b>302</b>	<b>Documents for Informing Investigators</b>

		A	Developing and Revising the IB
<b>IV</b>	<b>SS</b>	<b>400</b>	<b>STUDY START-UP</b>
		<b>401</b>	<b>Investigator Selection and Qualification</b>
		A	Investigator Qualification
		B	Investigator Agreements
		C	Disqualified Investigators
		<b>402</b>	<b>Initiation Visit and Site Training</b>
		A	Initiation Visit Preparation
		B	Investigative Site Training
		C	Documenting the Initiation Visit
<b>V</b>	<b>PM</b>	<b>500</b>	<b>PROJECT MANAGEMENT</b>
		<b>501</b>	<b>Communications</b>
		A	General Communications
		B	Communications with IRB
		C	Communications with Investigators and Site Staff
		D	Communications Records
		<b>502</b>	<b>Investigational Product Inventory Management</b>
		A	Labeling and Release of Investigational Product
		B	Investigational Product Receipt, Storage and Issue
		C	Investigational Product Accountability
		<b>503</b>	<b>Documentation and Records Retention</b>
		A	Creating the RMF
		B	Maintenance of the RMF
		<b>504</b>	<b>Routine Monitoring Visits</b>
		A	Scheduling/Frequency of Visits
		B	Preparation for a Monitoring Visit
		C	Conducting a Monitoring Visit
		<b>505</b>	<b>Study Closeout Visit</b>
		A	Site Closeout for Completion of Study
		B	Suspension for Inadequate Enrollment
		C	Suspension of Study by FDA or the IRB
		<b>506</b>	<b>Ensuring Investigator Compliance</b>
		A	Deviations from the Protocol (Protocol Violations) and Requests for Waivers
		B	Termination of Research for Protocol Violations
<b>VI</b>	<b>SM</b>	<b>600</b>	<b>SUBJECT MANAGEMENT</b>
		<b>601</b>	<b>Human Subject Protection</b>
		A	IRB Submissions and Review
		B	Informed Consent Process
		C	Waiver of Consent for Research in an Emergency Setting
		D	Emergency Use of an Investigational Product
		<b>602</b>	<b>Subject Recruitment Practices</b>
		A	Sponsor-Produced Materials
		B	Investigator-Produced Materials
		<b>603</b>	<b>Subject Eligibility and Enrollment</b>
		A	Subject Eligibility Documentation
		B	Conduct of Screening Activities at the Site

		<b>604</b>	<b>Specimen Management</b>
		A	Assessing Site's Specimen Management Capability
		B	Specimen Handling and Retention Requirements
		<b>605</b>	<b>Adverse Event Recognition and Reporting</b>
		A	Identifying AEs
		B	Management and Documentation of AEs
		C	Reporting Procedures for Serious AEs
		<b>606</b>	<b>Protected Health Information</b>
		A	General Sponsor Activities
		B	Determining Covered Entity Status
		C	Working with Covered Entities as Clinical Trial Sites
		D	Authorization and Informed Consent
		E	Subject Recruitment
		F	Subject Access to Source Documents
<b>VII</b>	<b>DM</b>	<b>700</b>	<b>DATA MANAGEMENT</b>
		<b>701</b>	<b>Clinical Data Management</b>
		A	Data Collection and Transcription
		B	Data Management and Retention
		<b>702</b>	<b>Use of Electronic Data Management Systems</b>
		A	Electronic Systems Set-up
		B	Electronic Data Collection and Management
<b>VIII</b>	<b>QA</b>	<b>800</b>	<b>QUALITY ASSURANCE</b>
		<b>801</b>	<b>Quality Assurance Audits</b>
		A	Internal Audits
		B	Audits by Third Parties
		C	Auditing the Investigative Site
		<b>802</b>	<b>FDA Inspections</b>
		A	Preparing for an FDA Inspection
		B	Conducting the Inspection
<b>IX</b>	<b>IA</b>	<b>900</b>	<b>INTERIM ANALYSIS</b>
		<b>901</b>	<b>Assessing Need for a DMC</b>
		A	Evaluating the Protocol to Determine Need for a DMC
		<b>902</b>	<b>Establishing a DMC</b>
		A	Planning the DMC
		B	Developing DMC SOPs
<b>X</b>			<b>ATTACHMENTS</b>